Browse articles from EyeWorld.org related to gene therapy. EyeWorld is the award-winning member publication of ASCRS. The magazine provides news and updates from the Society as well as clinical features in the areas of cataract, refractive, cornea, glaucoma, and practice management. It publishes quarterly with editorial direction from its medical editorial board and staff.
➤ Enrollment complete in Phase 3 trial for wet AMD ➤ Dosing complete in Phase 1/2 trial for retinitis pigmentosa treatment ➤ First patient dosed in gene therapy study for optic nerve disorder ➤ Company news
➤ Study: low-dose pilocarpine reduces pupil diameter without significant ciliary muscle response ➤ First patient receives investigational surgical system for glaucoma ➤ Clinical program for RP gene therapy begins ➤ FDA approves IND for steroid-free, topical anti-inflammatory ➤ Compassionate use approved for investigational drug intended for neuropathic corneal pain ➤ Company news ➤ ASCRS news and events
➤ Enrollment complete in first-in-human trial evaluating treatment for patients with Usher syndrome ➤ First patients randomized in drug-eluting IOL trial ➤ Preliminary data from Phase 2 gene modifier study for geographic atrophy ➤ ASCRS news and events
➤ Study: ‘revolutionary,’ ‘world-first’ treatment for vision-threatening condition restores sight ➤ IDE granted to tissue-based presbyopia solution ➤ Fast Track designation granted for geographic atrophy treatment ➤ Phase 1 results for Stargardt gene therapy ➤ Topline Phase 1b results from study comparing a next-gen treatment to faricimab ➤ Enrolled patients complete dosing in part of trial evaluating X-linked retinoschisis therapy ➤ Company news ➤ ASCRS news and events
➤ Meeting with FDA to advance therapy for Leber congenital amaurosis ➤ 36-month data from first-in-human bimatoprost-IOL system ➤ 20-week data from study evaluating treatment for patients with macular edema secondary to inflammation ➤ Interim data from Phase 1/2 trial for wet AMD therapy ➤ Company news ➤ ASCRS news and events
➤ Phase 1/2 trial update for Leber congenital amaurosis gene therapy in pediatric patients ➤ Primary endpoint not met in Phase 2b trial investigating persistent corneal epithelial defect treatment ➤ Study: treatment for uveal melanoma could improve survival rate ➤ Company news ➤ ASCRS news and events
➤ Priority review granted to possible LHON treatment ➤ Update on drug in development for neuropathic corneal pain ➤ FDA approves generic bimatoprost ➤ Phase 1/2a clinical results for first-in-human retinal pigment epithelial stem cell therapy ➤ Adult dosing complete in trial for X-linked retinoschisis therapy ➤ Company news ➤ ASCRS news and events
➤ Phase 2 trial is the ‘first and only’ to show vision improvement for Stargardt disease ➤ IND accepted for retinal disease gene therapy and Phase 1/2 trial to begin ➤ First patients dosed in trial evaluating retinitis pigmentosa treatment ➤ LASIK alternative being researched ➤ Partnership news ➤ ASCRS news and events
➤ First gene therapy treatment for macular telangiectasia type 2 performed outside of trial ➤ First patient enrolled in Phase 2b study of ocular micro implant for IOP reduction ➤ Fast Track Designation granted to Stargardt gene therapy ➤ FDA Special Protocol Assessment for non-proliferative diabetic retinopathy trial ➤ IDE granted to new glaucoma therapy system ➤ Partnership news ➤ ASCRS news and events
➤ Phase 3 results for preservative-free redness reliever ➤ Enrollment complete in Phase 3 pivotal program for wet AMD treatment ➤ Dry AMD Phase 3 trial completes enrollment ➤ Study: 24-month data confirm durability of dry eye procedural treatment ➤ Partnership and acquisition news ➤ ASCRS news and events